Cold chain packaging has some concerns to keep in mind. Kevin Lawler, healthcare packaging columnist, recently pointed out its three main current issues.[hr]
Picture all the concerns and difficulties of regular packaging industries, such as paper or plastics packaging. Now, add the trouble of managing temperatures and temperature excursions all the way up. What you’ll get is known as cold chain packaging, or how to deal with temperature-sensitive biologics.
Cold chain packaging is as complicated as it sounds ─ maybe even more. We talked a little bit about the latest trends in the field some weeks ago, but now, it’s time to talk about the focus points: the main current issues packaging industries are trying to conquer.
To ease the process, we turned out to Kevin Lawler’s recent thoughts on a Packaging World guest column:[quote style=”boxed”]“Protecting payloads from temperature excursions isn’t the only pain point customers look to solve when evaluating temperature-controlled packaging. Three priorities customers have when making cold chain packaging purchasing decisions include ensuring regulatory compliance, reducing overall costs, and establishing cold chain lanes in emerging markets.”[/quote]
Regulations, it turns out, seem to be a significant concern in the cold chain packaging field. It’s to be expected, after all, when dealing with something that could “mean the difference between profit and loss, but also life and death”, Lawler says. The fundamental standards to have in mind, he points out, range from: the European Union’s 2013 GDP Guidelines, to the Parenteral Drug Association’s and the E.U.’s strict GDP, quality, health and safety standards, just to say some.
Lawler also gave some keys to reducing costs in the process of compliance:[quote style=”boxed”]“Shippers with less weight and greater volumetric efficiency can offer financial advantages of lower transport cost, as a result of less shipping weight. In addition, reusable cold chain packaging, such as the Crēdo Cube™, help reduce cost per use. Selecting a shipper with greater payload capacity can also assist in reducing overall cost.”[/quote]
But what about the market? Regulations and cost reductions don’t bring growth ─ but emerging markets do, and that’s the third key Lawler points out. The BioPharma Cold Chain 2014 Sourcebook, from Healthcare Commerce Media Corp., predicted that “cold chain logistics spending will expand from $8 billion in 2014 to more than $10 billion by 2018.” That’s a two billion increase, in just four years, at a half-a-billion-per-year rate.
But that’s not to say it will be easy. Lawler advice for those interested to getting involved are:[quote style=”boxed”]“A global network of manufacturing and asset optimization services, in addition to close partnerships with third-party logistics organizations, are just a few of the ways to guide customers seeking to establish integrity in emerging markets.”[/quote]
Guidance won’t make it by itself, but hard work might. If interested, you should start moving. Like, right now.
Don’t let things cool off.
Sponsored by Derprosa, leading brand in biaxially oriented polypropylene films for packaging.